Tier 2 — strong

Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease

Nicola P Bondonno, Catherine P Bondonno, Natalie C Ward, Richard J Woodman, Jonathan M Hodgson, Kevin D Croft
The British journal of nutrition 2020 123(2):182-189

Bibliography

PubMed
PMID 31870463
DOI
10.1017/S0007114519002137
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized controlled acute crossover study
ModelHuman intervention research
Sample25 adults with at least one cardiovascular risk factor
InterventionEnzymatically modified isoquercitrin, 2 mg/kg quercetin-aglycone equivalent, versus placebo with breakfast
DurationSingle-dose assessment, including 1.5-hour vascular testing
EndpointsBlood pressure; Exposure and pharmacokinetics; Cognitive, mood, or sleep measures

What the study showed, in plain terms

Published in 2020, this source examined forms, absorption and food sources. Design: Randomized controlled acute crossover study. Sample/model: 25 adults with at least one cardiovascular risk factor. The exposure or intervention was Enzymatically modified isoquercitrin, 2 mg/kg quercetin-aglycone equivalent, versus placebo with breakfast. Follow-up or treatment period: Single-dose assessment, including 1.5-hour vascular testing.

Flow-mediated dilation and circulating metabolites increased. Blood pressure, arterial stiffness and cognition did not change.

Acute glycoside study. A transient vascular response is not evidence of fewer cardiovascular events.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Flow-mediated dilation and circulating metabolites increased.
  • Blood pressure, arterial stiffness and cognition did not change.
  • The recorded outcome domains were Blood pressure; Exposure and pharmacokinetics; Cognitive, mood, or sleep measures.
  • The result applies to the tested exposure: Enzymatically modified isoquercitrin, 2 mg/kg quercetin-aglycone equivalent, versus placebo with breakfast; Single-dose assessment, including 1.5-hour vascular testing.

What this study can and cannot tell us

  • Acute glycoside study. A transient vascular response is not evidence of fewer cardiovascular events.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology